Eurofins Scientific SE Stock (FR0014000MR3): UL Solutions to Acquire Eurofins E&E Business for €575 Million Enterprise Value, Announced April 13, 2026

Eurofins Scientific SE has agreed to sell its electrical and electronics (E&E) business to UL Solutions Inc. for an enterprise value of approximately €575 million, with the transaction announced on April 13, 2026. The deal reflects Eurofins’ strategic focus on core testing and life sciences activities while providing UL Solutions with expanded capabilities in product safety and compliance testing for the global E&E sector.

Eurofins Scientific SE has agreed to sell its electrical and electronics (E&E) business to UL Solutions Inc. for an enterprise value of approximately €575 million, with the transaction announced on April 13, 2026. The deal reflects Eurofins’ strategic focus on core testing and life sciences activities while providing UL Solutions with expanded capabilities in product safety and compliance testing for the global E&E sector.

According to UL Solutions’ first?quarter 2026 earnings release dated April 13, 2026, the company entered into a definitive agreement to acquire Eurofins’ E&E business, which includes testing, inspection, and certification services for electrical and electronic products. The transaction is structured as an enterprise?value deal of about €575 million, with UL Solutions assuming related liabilities and integrating the acquired operations into its existing global network of laboratories and certification services. The announcement was made in a press release titled “UL Solutions Inc. Reports Strong First Quarter 2026 Results,” which also disclosed the acquisition alongside the company’s quarterly financial results.

UL Solutions highlighted that the acquisition will strengthen its position in the global E&E testing and certification market, adding Eurofins’ technical expertise, customer base, and laboratory footprint in key regions. The E&E business being sold by Eurofins provides services across product safety, electromagnetic compatibility, environmental testing, and regulatory compliance for manufacturers of consumer electronics, industrial equipment, and other electrical products. UL Solutions expects the integration to enhance its ability to serve multinational clients with end?to?end testing and certification solutions, particularly in fast?growing technology and industrial segments.

For Eurofins Scientific SE, the divestiture represents a strategic realignment of its portfolio toward higher?growth and more capital?efficient testing segments, including food, environmental, pharmaceutical, and clinical diagnostics. The company has not disclosed detailed financial metrics for the E&E business in the public announcement, but the €575 million enterprise value implies that the unit contributes a meaningful but non?core portion of Eurofins’ overall revenue and earnings. By monetizing this business, Eurofins can redeploy capital into organic growth initiatives, digitalization, and potential acquisitions in its core life sciences and testing verticals.

The transaction is subject to customary closing conditions, including regulatory approvals and other standard closing requirements. UL Solutions did not specify a precise closing date in its April 13, 2026 release, but indicated that the deal is expected to close in the second half of 2026, assuming timely satisfaction of conditions. Until closing, the E&E business will continue to operate as part of Eurofins’ group structure, with no immediate changes to customer contracts or service delivery.

From a financial?reporting perspective, Eurofins will treat the E&E business as a discontinued operation once the sale is completed, with the proceeds and any gain or loss on disposal reflected in the relevant reporting period. The company has not yet provided updated guidance that incorporates the impact of the divestiture, but investors can expect management to address the transaction’s implications for revenue, EBITDA, and cash flow in future earnings communications. The €575 million enterprise value will be recorded as cash proceeds, net of transaction costs and any assumed liabilities, and may be used to strengthen the balance sheet, fund share buybacks, or finance additional strategic investments.

Market reaction to the announcement has been mixed, with Eurofins’ shares trading in a volatile range since early April 2026. On the Euronext Paris exchange, Eurofins Scientific SE (ticker: ERF) traded at approximately €59.20 on May 7, 2026, according to Google Finance data, reflecting a market capitalization of about €10.65 billion. The stock has underperformed its 50?day and 200?day moving averages in recent weeks, with the 50?day average around €75.46 and the 200?day average near €74.89, indicating a short?term downtrend despite the positive strategic implications of the UL Solutions deal.

Analyst coverage of Eurofins remains cautious, with a mix of buy, hold, and underperform ratings across different institutions. Jefferies, for example, has rated the stock “Underperform” with a price target of €48, reflecting skepticism about near?term growth acceleration and the dilutive impact of recent acquisitions and integration efforts. Other analysts have maintained neutral or hold ratings, citing the company’s solid underlying growth in core testing segments but also highlighting execution risks and margin pressure in a competitive environment. The UL Solutions transaction may prompt some analysts to revise their models, particularly if the proceeds are used to reduce leverage or fund higher?return growth initiatives.

From a business?model perspective, Eurofins Scientific SE operates as a global leader in analytical testing services, with a broad portfolio spanning food, environmental, pharmaceutical, clinical diagnostics, and industrial testing. The company’s laboratories and service centers are located across Europe, North America, and Asia, serving a diverse client base that includes manufacturers, regulators, and public?sector organizations. Eurofins’ revenue model is largely fee?based, with contracts ranging from short?term project work to long?term outsourcing agreements, providing relatively stable cash flows and recurring revenue streams.

In 2024, Eurofins reported revenue of approximately €6.95 billion, representing year?on?year growth of about 6.7% compared with €6.51 billion in 2023. Net income for 2024 was around €356.3 million, up roughly 38.9% from the prior year, reflecting improved operating leverage and cost?efficiency initiatives. The company’s earnings before interest, taxes, depreciation, and amortization (EBITDA) also increased, supported by higher utilization of laboratory capacity and digitalization of testing workflows. These figures are based on publicly available financial data compiled by third?party platforms and are consistent with Eurofins’ own disclosures in its annual and interim reports.

Looking ahead, Eurofins’ management has indicated that the company expects revenue growth of approximately 8.6% in the current fiscal year, assuming continued demand for testing services in food safety, environmental monitoring, and life sciences. The company also maintains a share?repurchase program that contemplates buying back up to 4.5% of its share capital between April 2025 and April 2026, subject to market conditions and regulatory requirements. These initiatives are designed to enhance shareholder value by returning excess capital while maintaining sufficient liquidity for strategic investments.

The divestiture of the E&E business to UL Solutions is consistent with Eurofins’ broader strategy of focusing on high?margin, high?growth testing segments and optimizing its portfolio through selective acquisitions and disposals. By exiting the E&E testing market, Eurofins can concentrate resources on areas where it has stronger competitive advantages, such as food and environmental testing, clinical diagnostics, and specialized life?sciences services. The transaction also reduces exposure to cyclical industrial demand and regulatory changes in the E&E sector, which can be subject to rapid technological shifts and evolving safety standards.

For UL Solutions, the acquisition of Eurofins’ E&E business represents a significant expansion of its global testing and certification footprint. UL Solutions already operates a large network of laboratories and certification services worldwide, and the addition of Eurofins’ E&E operations will enhance its ability to serve multinational clients with integrated solutions for product safety, performance, and compliance. The €575 million enterprise value reflects the strategic value of the acquired business, including its technical expertise, customer relationships, and regulatory accreditations in key markets.

Investors in Eurofins Scientific SE should consider several factors when assessing the impact of the UL Solutions transaction. First, the €575 million proceeds will provide a one?time boost to cash flow, which management can use to strengthen the balance sheet, fund share buybacks, or invest in growth initiatives. Second, the divestiture may lead to a modest reduction in reported revenue and earnings, but the company’s focus on higher?margin segments could improve overall profitability and return on capital. Third, the transaction reduces portfolio diversification and increases concentration in certain testing verticals, which may affect risk exposure in the event of sector?specific downturns.

From a valuation perspective, Eurofins currently trades at a price?to?earnings (P/E) ratio of about 27.7x based on trailing earnings, according to Investing.com data, with a forward P/E of approximately 18.9x. The stock’s price?to?book ratio is around 1.8x, and its price?to?sales ratio is about 1.4x, indicating that the market assigns a moderate premium to the company’s earnings and growth prospects. The recent underperformance relative to moving averages suggests that investors may be pricing in execution risks and uncertainty about the impact of the UL Solutions deal on future earnings.

For US investors, Eurofins Scientific SE is relevant as a global testing and life?sciences services provider with significant operations in North America and exposure to US regulatory frameworks. The company’s services support US?based manufacturers, food producers, and healthcare organizations, and its testing activities are subject to US standards and regulations in areas such as food safety, environmental protection, and medical?device compliance. The UL Solutions transaction will not materially alter Eurofins’ US footprint, but it may influence the competitive landscape for E&E testing services in the region, as UL Solutions integrates the acquired business into its existing operations.

In summary, Eurofins Scientific SE’s agreement to sell its electrical and electronics (E&E) business to UL Solutions Inc. for an enterprise value of approximately €575 million, announced on April 13, 2026, represents a strategic portfolio realignment that strengthens both companies’ positions in their respective markets. For Eurofins, the transaction supports a focus on core testing and life?sciences activities while providing a significant cash inflow that can be used to enhance shareholder value. For UL Solutions, the acquisition expands its global E&E testing and certification capabilities, reinforcing its role as a leading provider of product safety and compliance services. Investors should monitor the closing of the deal, the integration process, and any updates to Eurofins’ financial guidance as key factors influencing the stock’s performance in the coming quarters.